血红蛋白类氧载体在肿瘤治疗领域中的应用进展
Application progress of hemoglobin-based oxygen carriers(HBOCs)in tumor therapy
郑诗凡 1王红 1徐莹璨 1吴嘉康 1周文涛 1郝莎莎1
作者信息
- 1. 中国医学科学院北京协和医院输血研究所,四川 成都 610052
- 折叠
摘要
大多数实体肿瘤内血流和氧气供氧不足,缺氧微环境会加速肿瘤恶化,影响肿瘤预后.因此,改善肿瘤组织的氧合状态对提高肿瘤治疗敏感性和有效性至关重要.血红蛋白类氧载体(hemoglobin-based oxygen carriers,HBOCs)是一类携释氧纳米粒子,可到达正常红细胞难以通过的障碍性微循环小血管,为缺氧的组织器官输送氧气.已有研究证明,HBOCs作为 1 种潜在的纳米级高效携/释氧剂应用于肿瘤治疗可以增加组织氧合,在肿瘤治疗领域具有巨大应用前景.本文综述了缺氧在肿瘤中的影响,并重点介绍了血红蛋白类氧载体在肿瘤放疗、化疗、新型动力学治疗和免疫治疗领域的应用进展及可能机制.
Abstract
Most solid tumors suffer from inadequate blood perfusion and oxygenation,leading to a hypoxic microenviron-ment that accelerates tumor progression and adversely impacts prognosis.Thus,improving oxygenation in tumor tissues is crucial for enhancing the sensitivity and efficacy of tumor therapy.Hemoglobin-based oxygen carriers(HBOCs),as a type of oxygen-carrying nanoparticles,can not only carry and release oxygen but also reach the small blood vessels of obstructive mi-crocirculation to deliver oxygen for anoxic tissues and organs,which are difficult for normal red blood cells to pass through.Studies have demonstrated that the application of HBOCs as a potential nanoscale efficient oxygen carrier in tumor therapy can enhance tissue oxygenation and hold great promise for applications in tumor therapy.This review summarizes the impact of hypoxia in tumors and highlights the progress and potential mechanisms of using HBOCs in tumor radiotherapy,chemo-therapy,new kinetic therapy and immunotherapy.
关键词
血红蛋白类氧载体/肿瘤微环境/肿瘤缺氧/肿瘤治疗Key words
hemoglobin-based oxygen carriers(HBOCs)/tumor microenvironment/tumor hypoxia/tumor therapy引用本文复制引用
基金项目
中国医科院医学与健康科技创新工程项目(2021-I2M-1-060)
出版年
2024
国家科技期刊平台
NSTL
万方数据